<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02266550</url>
  </required_header>
  <id_info>
    <org_study_id>543.16</org_study_id>
    <nct_id>NCT02266550</nct_id>
  </id_info>
  <brief_title>Metabolism and Pharmacokinetics of [14C]-BIIL 284 BS in Healthy Volunteers</brief_title>
  <official_title>Investigation of Metabolism and Pharmacokinetics of [14C]-BIIL 284 BS After Administration of a Single Oral Dose of 25 mg [14C]-BIIL 284 BS in 6 Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The aims of this phase I study are to define the metabolism, excretion and pharmacokinetics
      of [14C]-BIIL 284 BS after administration of a single oral dose of 25 mg [14C]-BIIL 284 BS in
      6 healthy volunteers. Tolerability was also assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 1999</start_date>
  <primary_completion_date type="Actual">October 1999</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rates and routes of excretion of total radioactivity</measure>
    <time_frame>up to 216 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of [14C] radioactivity in blood</measure>
    <time_frame>up to 216 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of [14C] radioactivity in excreta (urine, faeces)</measure>
    <time_frame>up to 216 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration of the analytes in plasma (Cmax)</measure>
    <time_frame>up to 216 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach Cmax (tmax)</measure>
    <time_frame>up to 216 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal half-life (t1/2)</measure>
    <time_frame>up to 216 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean residence time (MRT)</measure>
    <time_frame>up to 216 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the drug concentration-time curve extrapolated from zero to infinity (AUC0-inf)</measure>
    <time_frame>up to 216 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent clearance (CL/f)</measure>
    <time_frame>up to 216 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution (Vd/f)</measure>
    <time_frame>up to 216 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Nature of metabolites in plasma</measure>
    <time_frame>up to 8 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Nature of metabolites in urine</measure>
    <time_frame>up to 48 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Nature of metabolites in faeces</measure>
    <time_frame>up to 48 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Excretion balance on the basis of the [14C] radioactivity in urine and faeces</measure>
    <time_frame>up to 216 hours after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant changes in laboratory parameters</measure>
    <time_frame>up to 216 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant findings in physical examination</measure>
    <time_frame>up to 216 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant changes in vital signs</measure>
    <time_frame>up to 216 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant findings in 12-lead electrocardiogram</measure>
    <time_frame>up to 216 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>up to 216 hours after drug administration</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C] BILL 284 BS</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers, range from 30 to 55 years of age inclusive

          -  Body weight between 50 and 100 kg and within ± 20% of ideal body weight

          -  No clinically significant abnormal physical findings at the screening examination
             which would interfere with the objective of the study

          -  No clinically relevant abnormalities in the results of laboratory screening evaluation

          -  Normal ECG

          -  Normal Blood pressure (between 100 to 150 mmHg systolic and 50 to 90 mmHg diastolic)
             and heart rate (between 50 to 90 beats per minute)

          -  Able to communicate well with the investigator and to comply with the requirements of
             the entire study

          -  Provision of written informed consent to participate as shown by a signature on the
             volunteer consent form

          -  Non-smokers

        Exclusion Criteria:

          -  Medical examination or laboratory test results that are judged by the clinical
             investigator to differ significantly from normal clinical values

          -  Known gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Current disease of the central nervous system (such as epilepsy) or with psychiatric
             disorders)

          -  Known history of orthostatic hypotension, fainting spells or blackouts

          -  Chronic or relevant acute infections

          -  Intake of any drugs which might influence the results of the trial during the week
             previous to the start of the study

          -  Administration of any investigational drug in the period 3 months before entry to the
             study (4 months if the previous drug was a new chemical entity)

          -  A need for any medication within the two weeks before dosing

          -  Existence of any surgical or medical condition which, in the judgement of the clinical
             investigator, might interfere with the absorption, distribution, metabolism or
             excretion of the drug (e.g. renal or hepatic impairments)

          -  Presence of clinically relevant history of allergy/hypersensitivity (including drug
             allergy)

          -  Blood loss or donation within the last 12 weeks (≥ 400 ml)

          -  Serious adverse reaction/hypersensitivity to any drug

          -  Objection by the subject's general practitioner to his/her patient's participation in
             the study

          -  Positive results for drug screening as listed in the protocol, positive results for
             hepatitis B surface antigen, Anti hepatitis B core antibodies, Anti hepatitis C virus
             antibodies and human immunodeficiency test, Glucose 6 - Phosphate Dehydrogenase

          -  Inability to communicate or co-operate with the investigator due to language problem,
             poor mental development or impaired cerebral function

          -  Administration of radiolabelled substance or exposure to significant radiation (e.g.
             serial X-ray, or CT scans, barium meal, etc) within the past 12 months

          -  History of recent drug abuse

          -  Volunteers who drink more than 4 units of alcohol per day and/or have been consuming
             alcohol during the 24 hours before dosing

          -  Participation in excessive physical activities (e.g. competitive sports) within the
             last week before the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2014</study_first_submitted>
  <study_first_submitted_qc>October 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2014</study_first_posted>
  <last_update_submitted>October 16, 2014</last_update_submitted>
  <last_update_submitted_qc>October 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

